Beyond drug price: A comparison of overall costs of anti‐vascular endothelial growth factor therapy alternatives for neovascular age‐related macular degeneration in Norway

In our model, longer-acting agents reduced injection frequency and decreased overall treatment costs. These findings suggest that adopting longer-acting monotherapy could improve cost-efficiency in long-term nAMD management in Norway.